title: Duloxetine-related posterior reversible encephalopathy syndrome: A case report.
abstract: BACKGROUND
  Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin-norepinephrine reuptake inhibitor such as duloxetine is unclear.
  
  
  METHODS
  We report on a patient who developed PRES with a coma and myoclonus related to hypertensive encephalopathy a few days after starting duloxetine treatment. Magnetic resonance imaging was performed and catecholamine metabolites assayed.
  
  
  RESULTS
  The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsant therapy.
  
  
  CONCLUSIONS
  The clinical history, blood and urinary catecholamine and serotonin levels, and response to treatment strongly suggest that PRES was induced by duloxetine. Duloxetine should be added to the list of causes of PRES.
authors.affiliation: Intensive Care Unit Neurology and Stroke Department Pharmacology Unit Emergency Department, Centre Hospitalier de Versailles - Site André Mignot, rue de Versailles, Le Chesnay cedex Paris Descartes University, Sorbonne Paris Cité-Medical School INSERM U970, Paris Cardiovascular Research Center, Paris, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Zappella
authors.forename: François
authors.initials: F
authors.lastname: Perier
authors.forename: Fernando
authors.initials: F
authors.lastname: Pico
authors.forename: Catherine
authors.initials: C
authors.lastname: Palette
authors.forename: Alexandre
authors.initials: A
authors.lastname: Muret
authors.forename: Sybille
authors.initials: S
authors.lastname: Merceron
authors.forename: Andrei
authors.initials: A
authors.lastname: Girbovan
authors.forename: Fabien
authors.initials: F
authors.lastname: Marquion
authors.forename: Stephane
authors.initials: S
authors.lastname: Legriel
mesh_terms: D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D000068736:Duloxetine Hydrochloride / Q000009:adverse effects*; D005260:Female; D006801:Humans; D059906:Neuroimaging; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
chemical_list: D000928:Antidepressive Agents; D000068736:Duloxetine Hydrochloride